Taiwan-based generic and specialty drugmaker focused on CNS, oncology and other therapeutic generics, with global licensing deals.
Taiwan-based generic and specialty drugmaker focused on CNS, oncology and other therapeutic generics, with global licensing deals.
Sells generic drugs in Taiwan and Asia and in the US through marketing partners, while its approved plants also make drugs under contract for other companies. Licensing tie-ups with partners such as Japan's Kaken bring upfront and milestone payments on top of product sales.
In one line: A Taiwanese Teva, smaller scale.
Moat: narrow (regulatory licence, process know-how). US FDA/Japan-approved plants and licensing tie-ups give access generics rivals lack.
Headquarters: Taipei, Taiwan · Employees: 1,585
Size Lotus Pharmaceutical (1795.TW) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $921M, the 277th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$121.50 on 18 Nov 2026.
Performance Over six months the shares fell 37.0%, against -20.9% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 5th lowest of 20 in its peer set.
Growth Revenue grew 66.6% over the last twelve months (peer median +2.4%); the operating margin is 21.4% (peer median 7.1%).
Valuation It trades at 9.8× forward earnings against a peer median of 24.4× (cheapest of 9).
Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -18 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.9 points above its cost of capital (5.0% WACC).
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$31.1B | NT$20.5B | NT$18.6B | NT$17.0B | NT$14.6B |
| Revenue growth | — | +10% | +10% | +16% | — |
| Gross profit | NT$14.1B | NT$10.6B | NT$9.86B | NT$8.34B | NT$7.02B |
| EBITDA | NT$9.04B | NT$7.44B | NT$7.30B | NT$6.11B | NT$5.05B |
| Net income | NT$2.22B | NT$4.72B | NT$5.07B | NT$4.11B | NT$3.02B |
| Free cash flow | NT$2.32B | NT$6.18B | NT$5.81B | NT$1.21B | NT$3.16B |
| Capital expenditure | NT$5.01B | NT$4.35B | NT$1.47B | NT$3.28B | NT$3.07B |
| Total debt | NT$59.0B | NT$55.9B | NT$13.7B | NT$11.6B | NT$8.92B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Lotus Pharmaceutical 1795.TW | $921M | -37% | +67% | 21% | 9.8× | -3.7% |
| Scinopharm Taiwan 1789.TW | $435M | -2% | -5% | -4% | 39.4× | 2.1% |
| Zydus Lifesciences ZYDUSLIFE.NS | $12.8B | +18% | +24% | 17% | 30.0× | n/a |
| Sandoz SDZ.SW | $41.7B | +26% | +1% | 15% | 24.5× | 7.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1795.TW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -32.9% | -9.1% | 2nd lowest of 21 |
| 6-month return | -37.0% | -20.9% | 5th lowest of 20 |
| Distance from 52-week high | -67.1% | -46.6% | 2nd lowest of 21 |
| Revenue growth (TTM) | +66.6% | +2.4% | 3rd highest of 18 |
| Operating margin | 21.4% | 7.1% | 4th highest of 18 |
| Forward P/E | 9.8× | 24.4× | cheapest of 9 |
| Growth the price implies (Req g, 7 yrs) | -3.7% | 10.3% | 3rd least demanding of 12 |
| Growth delivered (Del g) | +13.8% | +4.9% | 4th highest of 12 |
| Hurdle (Req g minus delivered) | -17.5 pp | +2.8 pp | 2nd least demanding of 12 |
| ROIC minus cost of capital | +1.9 pp | -2.0 pp | 5th highest of 15 |
| EV / EBITDA | 9.1× | 12.5× | cheapest of 6 |
| Net debt / EBITDA | 5.7× | 1.8× | most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Lotus Pharmaceutical 1795.TW | Taiwan | $921M | -37% | +67% | 21% | 9.8× | -3.7% | +13.8% |
| Zhejiang Garden Biopharmaceutical 300401.SZ | China | $922M | -14% | +2% | 24% | 22.9× | 9.1% | +13.4% |
| Oscotec 039200.KS | South Korea | $923M | -32% | +510% | 59% | 50.2× | -10.2% | +18.1% |
| MoonLake Immunotherapeutics MLTX | United States | $918M | -37% | n/a | n/a | n/a | n/a | n/a |
| Immatics IMTX | United States | $913M | -46% | -44% | -589% | n/a | n/a | n/a |
| Bio-Thera Solutions 688177.SS | China | $929M | -23% | +24% | -44% | n/a | n/a | n/a |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $912M | -42% | -55% | -457% | n/a | n/a | n/a |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $936M | -10% | -43% | -42% | n/a | 10.3% | -13.7% |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $904M | -28% | +14% | 7% | n/a | 19.4% | -6.0% |
| KPC Pharmaceuticals 600422.SS | China | $940M | -6% | -41% | -10% | n/a | n/a | n/a |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $941M | -9% | -16% | 13% | n/a | 7.7% | -6.9% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $945M | -48% | +19% | 9% | 42.3× | 11.6% | +4.9% |
| Strides Pharma Science STAR.NS | India | $946M | -17% | +11% | 14% | 15.9× | 17.6% | +7.8% |
| Aktis Oncology AKTS | United States | $895M | -15% | +337% | -837% | n/a | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $895M | -14% | -6% | 3% | n/a | -7.6% | -0.7% |
| SSY 2005.HK | Hong Kong | $948M | +8% | -4% | 12% | 12.5× | 2.3% | -0.5% |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $959M | -21% | -27% | -19% | 21.4× | n/a | n/a |
| Latigo Biotherapeutics LTGO | United States | $882M | n/a | n/a | n/a | n/a | n/a | n/a |
| BeBetter Med 688759.SS | China | $960M | -58% | n/a | n/a | n/a | n/a | n/a |
| Nxera Pharma 4565.T | Japan | $974M | +46% | +24% | 14% | 25.8× | 17.7% | +27.3% |
| Sanofi Consumer Healthcare India SANOFICONR.NS | India | $869M | -26% | +23% | 36% | 28.1× | 17.7% | +22.7% |